Defatting strategies in the current era of liver steatosis

Liver steatosis is emerging as a major cause of chronic liver disease worldwide, mainly due to the increasing rate of obesity, type 2 diabetes, and metabolic syndrome. Because of the increased incidence of liver steatosis, many organs are currently declined for transplantation despite high demand an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazilescu, Laura Ioana, Selzner, Markus, Selzner, Nazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121960/
https://www.ncbi.nlm.nih.gov/pubmed/34027337
http://dx.doi.org/10.1016/j.jhepr.2021.100265
_version_ 1783692498216943616
author Mazilescu, Laura Ioana
Selzner, Markus
Selzner, Nazia
author_facet Mazilescu, Laura Ioana
Selzner, Markus
Selzner, Nazia
author_sort Mazilescu, Laura Ioana
collection PubMed
description Liver steatosis is emerging as a major cause of chronic liver disease worldwide, mainly due to the increasing rate of obesity, type 2 diabetes, and metabolic syndrome. Because of the increased incidence of liver steatosis, many organs are currently declined for transplantation despite high demand and waiting list mortality. Defatting strategies have recently emerged as a means of rapidly reducing liver steatosis to expand the pool of available organs. This review summarises advances in defatting strategies in experimental and human models of liver steatosis over the last 20 years.
format Online
Article
Text
id pubmed-8121960
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81219602021-05-20 Defatting strategies in the current era of liver steatosis Mazilescu, Laura Ioana Selzner, Markus Selzner, Nazia JHEP Rep Review Liver steatosis is emerging as a major cause of chronic liver disease worldwide, mainly due to the increasing rate of obesity, type 2 diabetes, and metabolic syndrome. Because of the increased incidence of liver steatosis, many organs are currently declined for transplantation despite high demand and waiting list mortality. Defatting strategies have recently emerged as a means of rapidly reducing liver steatosis to expand the pool of available organs. This review summarises advances in defatting strategies in experimental and human models of liver steatosis over the last 20 years. Elsevier 2021-03-13 /pmc/articles/PMC8121960/ /pubmed/34027337 http://dx.doi.org/10.1016/j.jhepr.2021.100265 Text en © 2021 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Mazilescu, Laura Ioana
Selzner, Markus
Selzner, Nazia
Defatting strategies in the current era of liver steatosis
title Defatting strategies in the current era of liver steatosis
title_full Defatting strategies in the current era of liver steatosis
title_fullStr Defatting strategies in the current era of liver steatosis
title_full_unstemmed Defatting strategies in the current era of liver steatosis
title_short Defatting strategies in the current era of liver steatosis
title_sort defatting strategies in the current era of liver steatosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121960/
https://www.ncbi.nlm.nih.gov/pubmed/34027337
http://dx.doi.org/10.1016/j.jhepr.2021.100265
work_keys_str_mv AT mazilesculauraioana defattingstrategiesinthecurrenteraofliversteatosis
AT selznermarkus defattingstrategiesinthecurrenteraofliversteatosis
AT selznernazia defattingstrategiesinthecurrenteraofliversteatosis

Ejemplares similares